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The small heat shock protein Hsp31 cooperates with
Hsp104 to modulate Sup35 prion aggregation
Kiran Aslam, Chai-jui Tsai, and Tony R. Hazbun
Department of Medicinal Chemistry and Molecular Pharmacology and the Purdue
University Center for Cancer Research, Purdue University, West Lafayette, IN, USA

ABSTRACT. The yeast homolog of DJ-1, Hsp31, is a multifunctional protein that is involved in several
cellular pathways including detoxiﬁcation of the toxic metabolite methylglyoxal and as a protein
deglycase. Prior studies ascribed Hsp31 as a molecular chaperone that can inhibit a-Syn aggregation in
vitro and alleviate its toxicity in vivo. It was also shown that Hsp31 inhibits Sup35 aggregate formation in
yeast, however, it is unknown if Hsp31 can modulate [PSIC] phenotype and Sup35 prionogenesis. Other
small heat shock proteins, Hsp26 and Hsp42 are known to be a part of a synergistic proteostasis network
that inhibits Sup35 prion formation and promotes its disaggregation. Here, we establish that Hsp31
inhibits Sup35 [PSIC] prion formation in collaboration with a well-known disaggregase, Hsp104. Hsp31
transiently prevents prion induction but does not suppress induction upon prolonged expression of Sup35
indicating that Hsp31 can be overcome by larger aggregates. In addition, elevated levels of Hsp31 do not
cure [PSIC] strains indicating that Hsp31 cannot intervene in a pre-existing prion oligomerization cycle.
However, Hsp31 can modulate prion status in cooperation with Hsp104 because it inhibits Sup35
aggregate formation and potentiates [PSIC] prion curing upon overexpression of Hsp104. The absence of
Hsp31 reduces [PSIC] prion curing by Hsp104 without inﬂuencing its ability to rescue cellular
thermotolerance. Hsp31 did not synergize with Hsp42 to modulate the [PSIC] phenotype suggesting that
both proteins act on similar stages of the prion cycle. We also showed that Hsp31 physically interacts
with Hsp104 and together they prevent Sup35 prion toxicity to greater extent than if they were expressed
individually. These results elucidate a mechanism for Hsp31 on prion modulation that suggest it acts at a
distinct step early in the Sup35 aggregation process that is different from Hsp104. This is the ﬁrst
demonstration of the modulation of [PSIC] status by the chaperone action of Hsp31. The delineation of
Hsp31’s role in the chaperone cycle has implications for understanding the role of the DJ-1 superfamily
in controlling misfolded proteins in neurodegenerative disease and cancer.
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INTRODUCTION
Amyloids are highly ordered cross b-sheet
protein polymers that are associated with a
broad range of neurodegenerative diseases
including Parkinson, Alzheimer, Huntington
and Prion diseases.1,2 Growth of amyloids
occurs by the nucleated polymerization of soluble proteins of a particular sequence.3,4 Many
proteins can polymerize to form amyloid when
provided an appropriate environment in vitro,
indicating this as inherent characteristic of polypeptides. Indeed, many recent studies have
shown the existence of beneﬁcial amyloids that
are important for survival of a host organism.5
Furthermore, the highly rigid structure of selfpropagating amyloids provides a possible tool
in designing a unique nanomaterial.6 Therefore,
it is important to study the process of amyloid
formation as well as its modulation.
Budding yeast Saccharomyces cerevisiae,
provides a useful model to understand the formation, modulation and disaggregation of amyloids including prions.7 One of the most
extensively studied yeast prions is formed from
the translation termination factor Sup35, which
has the normal function of releasing polypeptide chains from the ribosome upon encountering a stop codon. The prion form of Sup35
involves a self-perpetuating conformational
change that results in stop codon suppression
and translational read-through.8 This termination defect can be visualized easily in vivo by
nonsense suppression of a designed premature
stop codon in a gene that affects colony color,
thus providing a convenient phenotypic assay
to monitor [PSIC] prion.8
The propagation of [PSIC] prion in yeast is rigorously controlled by molecular chaperone
machinery including, Hsp104, Hsp70, Hsp40 and
their co-chaperones.9-12 Hsp104 is a member of
AAAC ATPase superfamily and its expression is
induced under stress to facilitate refolding and dissociation of protein aggregates.13,14 A moderate
level of Hsp104 is required for [PSIC] prion propagation as overproduction or deletion of Hsp104

cures the [PSIC] prion in yeast.15,16 Since,
Hsp104 disaggregates the misfolded protein after
heat shock, it is postulated that Hsp104 generates
“propagons” by fragmenting the prion polymers
that are available for further polymerization and
therefore maintain the prion propagation.7
Another model proposes that elevated levels of
Hsp104 cure [PSIC] prion by dissolution of the
prion seeds, the evidence for this model came
from the observation of the diffuse expression of
Sup35 tagged with GFP when Hsp104 was overexpressed in [PSIC] cells,17 and a large fraction of
soluble Sup35 was observed in the cell lysate of
[PSIC] with excess of Hsp104 expression.18
Recent studies also suggests that dissolution of
prion seed might be due to trimming activity of
Hsp104 in which Sup35 dissociates from the end
of the prion seed thus reduces its size without generating new seeds.19,20 Trimming activity of
Hsp104 is still present even when severing activity is inhibited by treatment of guanidine.20
Hsp104 collaborates with Hsp70 and Hsp40 families in dissolution of heat-damaged proteins as
well as prion propagation.21-26 Interestingly, different Hsp70 homologues have opposing effects
on [PSIC] in which the Ssa proteins antagonize
while the Ssb proteins potentiate [PSIC] curing by
elevated levels of Hsp104.10,27,28 Deletion of cochaperones of Hsp70/90 such as Sti1, Cpr7 and
Sis1, also inhibit [PSIC] curing by Hsp104
overexpression.10,25,29
In addition to Hsp104 and its assistant chaperones, small heat shock proteins such as
Hsp31, Hsp26 and Hsp42 also play a role in
disaggregation of misfolded proteins in
yeast.30-36 These proteins are highly expressed
under moderate stress and during late growth
phase for transition to stationary phase.35,37
Hsp42 and Hsp26 work synergistically to
inhibit prion formation and potentiate dissolution of Sup35 prion aggregates by distinct
mechanisms.30 Furthermore, Hsp26 or Hsp42
collaborate with Hsp70 and or Hsp104 to
reduce the SDS-resistant polyglutamine aggregation.31,38 Hsp31 is an ortholog of DJ-1, which
has been well established to have a role in
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neurodegenerative disease and more recently in
cancer.39,40 Hsp31 inhibits the formation of
a-Syn aggregates in vitro and toxicity in
vivo.41,42 It was also demonstrated that Hsp31
inhibits Sup35 aggregation formation in yeast41
however, it is unknown whether Hsp31 interferes with [PSIC] prion induction and propagation and if like other small heat shock proteins
it can coordinate with Hsp104.
In the present study, we aimed to explore the
role of Hsp31 in prion propagation and induction using [PSIC] prion model. First, we investigated the ability of Hsp31 to inhibit Sup35
prion aggregation and induction by overexpression of the prion-forming domain (PrD) in
[psi¡] strain. In this study we have delineated
the collaboration between Hsp31 and Hsp104
on [PSIC] prion curing and prion associated
toxicity. These results are the ﬁrst evidence that
Hsp31 acts as a chaperone protein that coordinates with Hsp104 to rescue cells from prion
toxicity.

RESULTS
Hsp31 Antagonizes Sup35 Aggregation
Formation in [psi¡PINC] strain
background
We previously reported that Hsp31 has
chaperone activity against Sup35 aggregates
when tested in the wild-type (WT) W303 yeast
strain. In this study, we validated the ability of

Hsp31 to inhibit Sup35 ﬁbril formation in the
[psi¡ PINC] strain background. [PINC], an
epigenetic element, is required to induce
[PSIC] formation spontaneously or by overexpression of Sup35 or its PrD.43 The presence
of [PINC] is necessary at early stages of prion
formation but is not needed for maintenance
and propagation of [PSIC].7 We overexpressed
Hsp31-DsRed under the GPD promoter concomitantly with PrD-Sup35-EYFP under GAL
expression in a [psi¡ PINC] 74D-694 strain.
We have previously shown the DsRed-tagged
Hsp31 is nearly functionally equivalent to an
untagged protein because it can complement a
hsp31D strain.41 When examined by confocal
microscopy, PrD-Sup35 ﬂuorescent foci were
greatly reduced in cells co-expressing
pAG415-GPD-HSP31-DsRed and pAG424GAL-PrD- Sup35-EYFP as compared to vector
control (Fig. 1A-B). We further conﬁrmed
reduced foci formation by measuring ﬂuorescence intensity using ﬂow cytometry and
obtained similar results as ﬂuorescence
microscopy (Fig. 1C). We have previously
observed and established that Sup35 aggregates are associated with increased ﬂuorescence and can be quantiﬁed using ﬂow
cytometry.41 Finally, we performed semi-denaturing detergent agarose electrophoresis (SDDAGE) to determine the level of SDS-resistant
aggregate forms. Consistent with the previous
results, elevated Hsp31 greatly reduced the
level of Sup35 aggregates as measured by
SDD-AGE but did not greatly reduce the

FIGURE 1. Hsp31 overexpression decreases the level of PrD-Sup35 aggregates. (A) GAL-driven
PrD-Sup35-EYFP was overexpressed for 24 h at 30 C in [psi¡ PINC] cells with or without overexpression of DsRed tagged Hsp31. PrD-Sup35-EYFP aggregates appeared as ribbon-like vacuolar peripheral rings. Hsp31 remains cytoplasmically diffuse in these cells. Elevated levels of Hsp31 decreased
the presence of Sup35 aggregates in individual cells. (B) Quantitation of the number of cells with one
or more Sup35-EYFP foci. The average of at least 3 independent experiments was plotted; error bars
represent mean §SEM. (*** unpaired Student’s t-test; p
0.001). (C) Quantitation of the level of
Sup35-EYFP fuorescence aggregates using fow cytometry. Aggregates are associated with higher
fuorescence. Elevated levels of Hsp31 lowered the median fuorescence intensity (FI – arbitrary units)
of Sup35-EYFP compared to vector control. Values represent mean §SEM of 3 independent biological
replicates (* unpaired Student’s t-test; p 0.01). (D) Cellular lysate of cells describe in A and B was
analyzed by semi-denaturing agarose electrophoresis and SDS-PAGE. Overexpression of Hsp31 suppresses the level of SDS-resistant Sup35 aggregates as detected with anti-GFP antibody. Lower panel
shows the expression of Hsp31 detected by anti-DsRed antibody.
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overall steady-state level of Sup35 in SDSPAGE (Fig. 1D). These results show that Hsp31
can reduce de novo [PSIC] aggregate formation,
as can be detected by SDD-AGE, in the pres-

ence of the [PINC] genetic element. It should be
noted that additional lower molecular weight
prion forms, that might not be detected by
SDD-AGE may persist and still be infectious.
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Hsp31 Transiently Inhibits Sup35 Prion
Induction in vivo
The ability of Hsp31 to inhibit Sup35 aggregation in the [psi¡ PINC] background led us to
investigate its ability to inhibit [PSIC] induction. Spontaneous de novo [PSIC] induction
frequency is extremely low unless Sup35 or its
PrD is overexpressed.8,44 This system is widely
used to investigate the process of prion induction in yeast. To determine whether Hsp31 can
inhibit prion induction we used a [psi¡ PINC]
strain that forms red color colonies on 1/ 4 YPD
plates with limited adenine. This strain forms
white colonies in the presence of [PSIC]
because soluble Sup35 is depleted by aggregate
formation resulting in suppression of a premature stop codon and restoration of adenine prototrophy. We observed that overexpression of
Hsp31 antagonized [PSIC] prion induction triggered by overexpression of Sup35 PrD for 6 h
(Fig. 2A-B). However, when Sup35 PrD was
expressed for 12 or 24 h, the [PSIC] prion
induction level between vector control and
Hsp31 was statistically similar (Fig. 2C). In
addition, we have previously shown that Hsp31
overexpression does not signiﬁcantly alter
Hsp104 expression levels.41 These ﬁndings
suggested that Hsp31 antagonizes prion induction transiently but can be overcome by excess
production of PrD or cannot intervene when
cells have established a full and more mature
prion cycle. In addition, the transient and nonpermanent effect on [PSIC] by overexpression
of Hsp31 suggests that the [PINC] prion is not
cured. These results are consistent with our

previous proposal that Hsp31 intervenes early
in the protein misfolding processes.41,45

[PSIC] Prion State is not Affected by
Hsp31 Overexpression or Deletion
Transient overexpression of small heat shock
proteins such as Hsp26 and Hsp42 cure the
[PSIC] prion, converting white or pink colonies
that reﬂect the strength of the [PSIC] phenotype, into red [psi¡] colonies on 1/ 4 YPD plates
with limited adenine.30 First, we tested if overexpression of Hsp31 can cure the [PSIC] prion.
We used the 74D-694 [PSIC] strain which has
a weak to moderate phenotype based on its
pink color. Despite the fact that Hsp31 can prevent de novo prion aggregate formation in vivo
as detected by SDD-AGE (Fig. 1), overexpression of Hsp31 is not sufﬁcient to cure the moderate [PSIC] phenotype of the 74D-694 strain
(Fig. 3A). In addition, Hsp42 was used as a
control and was able to cure [PSIC] as previously reported.28 However, we found that
Hsp26 overexpression using the identical plasmid vector from Duennwald et al.28 had 0 %
curing of [PSIC] in this strain and under these
experimental conditions in more than 3 biological replicates. Our results are more consistent
with Wickner and colleagues46 who reported
lack of prion curing by Hsp26 for both [Ure31] and [PSIC] phenotypes, which could be
explained by differences in strain genotypes
and experimental conditions.46 We tested different plasmid systems to express Hsp31
including the GPD and GAL promoters and

FIGURE 2. Hsp31 transiently inhibits Sup35 prion induction. (A) To induce prion formation, a GALdriven vector expressing PrD-Sup35-EYFP was expressed in the [psi¡ PINC] strain containing the
ade1-14 nonsense mutation. Constitutive expression of Hsp31 was driven by the GPD promoter and
[PSIC] formation was scored by quantifying white color colonies on 1/ 4 YPD plates. Top panel represents the vector controls for the expression plasmids in the bottom panel where Hsp31-DsRed, Hsp42
and Hsp104 were overexpressed. (B) PrD-Sup35-EYFP was expressed for 6 h to transiently induce
prion formation. Hsp31 overexpression decreased the prion induction level. Only one vector control is
shown because other vectors had similar levels of prion induction. Error bars represent §SEM (**
unpaired Student’s t-test; p 0.001, n D 3). (C) Time course of prion formation by pAG424-GAL-PrDSup35-EYFP with varied expression times in the presence of GPD-Hsp31. Error bars represent mean
§SEM (** unpaired Student’s t-test; p 0.001, n D 3) ns D not signifcant. All experiments in this fgure
were biological replicates.
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none of them were able to modulate the [PSIC]
prion phenotype (data not shown). Next, we
determined if deletion of HSP31 inﬂuences the
[PSIC] prion status. We constructed a [PSIC
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PINC] hsp31D strain carrying the reporter nonsense allele ade1-14, so that the Sup35 readthrough caused by [PSIC] presence could be
detected by development of white colonies.
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The phenotype of the [PSIC] prion was similar
in the hsp31D strain compared to WT with no
change in colony color (Fig. 3B), suggesting
that Hsp31 cannot intervene in an established
prion cycle.

Hsp31 Deletion Impairs [PSIC] Prion
Curing by Hsp104 Overexpression
A moderate level of Hsp104 is required for
maintenance of [PSIC]; either deletion or overexpression of Hsp104 cures the [PSIC] prion.
Numerous chaperones such as Hsp70, Hsp40
and Hsp90 along with its co-chaperones Sti1
and Cpr7 are known to modulate prion curing
by Hsp104.10,23 To determine if Hsp31 altered
Hsp104-mediated [PSIC] prion curing, we
transformed WT [PSIC] or hsp31D [PSIC] cells
with p426-GPD-Hsp104 (low level of overexpression),
pAG425-GAL-Hsp104-DsRed
(medium overexpression) or p2HG-Hsp104
(high overexpression) plasmids (Fig. 3C-E).
The varied overexpression level of Hsp104
under these different plasmid systems was conﬁrmed by western blotting (Fig. 3F). The level
of [PSIC] prion curing was correlated to the

level of Hsp104 expression in WT [PSIC] cells.
The level of [PSIC] prion curing was signiﬁcantly reduced in hsp31D [PSIC] under the lowest overexpression condition of GPD-Hsp104
(2% compared to 7% in WT) (Fig. 3C). Under
high overexpression of Hsp104, a 100% curing
level was observed in the presence of HSP31
but the hsp31D strain never achieved 100%
curing and clearly white colonies were
observed at 3% frequency (Fig. 3D). Intriguingly, the colonies were much whiter compared
to the parental strain before attempting
Hsp104-mediated curing, suggesting the colonies have a stronger [PSIC] status and phenotype but the reason for this is unclear. We
conﬁrmed that these colonies do not carry
extragenic suppressor mutations because treatment with guanadine hydrochloride cured the
[PSIC] phenotype as evidence by reversion to a
red color (data not shown). Induction of the
GAL-Hsp104-DsRed construct for varied time
points from 2 h to 72 h also showed consistently less efﬁcient prion curing by the hsp31D
strain (Fig. 3E). These results demonstrate the
presence of Hsp31 is required for optimal prion
curing efﬁciency at varied Hsp104 expression
conditions.

FIGURE 3. Hsp31 is required for optimal Hsp104-induced curing of the [PSIC] phenotype. (A) To
determine the effect of Hsp31 on [PSIC] prion curing, the WT and hsp31D [PSIC] strains harboring
the GPD-Hsp31 expression vector (pAG415-GPD-Hsp31-DsRed) or the vector (pAG415-GPDccdB-DsRed) were grown for 12 h at 30 C before plating on 1/ 4 YPD plates. (B) The WT and
hsp31D [PSIC] strains with no vector were also grown and treated in the same way. Plates were
grown for 2–3 d at 30 C and transferred at 4 C for increased color development. No difference in
colony color was observed in these strains. (C) Low-level overexpression of Hsp104 was used to
induce prion curing in [PSIC] hsp31D and WT strains. Cells were grown in liquid media for 12 h at
30 C before plating on 1/ 4 YPD plates. Signifcantly less prion curing was observed in the [PSIC]
hsp31D strain (**unpaired Student’s t-test; p
0.001, n D 3). (D) High-level overexpression of
Hsp104 was used to induce prion curing in [PSIC] hsp31D and WT strains. A 100% curing level was
observed in WT strain. In the [PSIC] hsp31D strain, 100% curing was never achieved. White color
colonies were plotted for the WT and [PSIC] hsp31D strain (****unpaired Student’s t-test; p
0.0001, n D 3 biological replicates). (E) Hsp104 expression under the GAL promoter for 2 to 72 h
in WT and [PSIC] hsp31D strain. At each indicated time point, cells were plated on 1/ 4 YPD plates.
Percentage of prion curing was calculated at each point for both WT and [PSIC] hsp31D strain. The
plotted graph is one representation of 3 independent biological repeats. (unpaired Student’s t-test;
p 0.001 at 24, 48 and 72 h; n D 3). (F) Western blot demonstrating the relative expression levels
of Hsp104. Time points for the pGAL plasmid are represent time after switching the strain to inducing galactose media. Equal amount of cells lysates were loaded in each lane and anti-histone H3
antibody was used as a loading control.
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Hsp31 Collaborates with Hsp104 to Cure
[PSIC] Prion
The decreased efﬁciency in Hsp104 curing
[PSIC] in the absence of Hsp31 lead us to further explore the relationship between these 2
chaperones. Small heat shock proteins Hsp26
and Hsp42 are known to collaborate with
Hsp104 in rescuing the polyglutamine toxicity
and solubilization of amyloid aggregates.31 We
focused on the collaboration of Hsp104 with
Hsp31 but it should be noted that a variety of
other co-chaperones may also be involved but
are beyond the scope of this study. Overall, the
results we present herein are indicative of a
direct effect of Hsp31 on [PSIC] as outlined in
the discussion. We ﬁrst tested the effect of
expressing Hsp31 and Hsp104 together in curing of the [PSIC] prion. Expression of Hsp104
(p426-GPD-Hsp104) in the [PSIC] strain
resulted in a curing frequency of 3 % that is
lower than that observed in Fig. 3 because the
co-existence of 2 different constructs presumably decreases plasmid copy numbers and
affects expression levels which we have
observed previously when expressing GALSup35-EYFP in combination with other vector
plasmids41 and has been noted previously by
others.47 Co-expression of Hsp31 and Hsp104
increased the frequency of prion curing to 6 %
compared to the respective controls (Fig. 4A).
We also tested the collaboration between
Hsp104 and Hsp31 in the hsp31D strain and
detected that co-expression of Hsp104 with
Hsp31 was able to cure the [PSIC] prion to a
greater extent than individual chaperone
expression (Fig. 4B). These results corroborate

the inefﬁcient curing in hsp31D and establish
that Hsp31 is required for optimal Hsp104
activity.
Previously, it was shown that small heat
shock protein, Hsp42, collaborates with Hsp26
to prevent [PSIC] prionogenesis by distinct and
synergistic mechanisms with Hsp10430 hence
we tested the interaction between Hsp42 and
Hsp31 on [PSIC] prion curing. Elevated levels
of Hsp42 driven by the GPD promoter was sufﬁcient to increase curing of [PSIC] in this strain
transformed with a single plasmid (5.4% compared to 1.4%). Introduction of a second vector
control plasmid, decreases the curing efﬁciency
of the GPD-HSP42 construct to background
levels. We also co-expressed Hsp31 and Hsp42
in the [PSIC] strain and did not detect any
increased curing efﬁciency, in contrast to
Hsp31 co-expression with Hsp104 (Fig. 4C).
This lack of synergy between these proteins
implies that Hsp42 and Hsp31 act at a similar
stage of the prion cycle.

Effect of [PSIC] Curing in the hsp31D
Strain is not Due to Loss of Hsp104
Thermotolerance Function
A possible mechanism for the decrease in
[PSIC] prion curing by Hsp104 in the hsp31D
background is decreased expression or activity
of Hsp104. To measure the functional competence of Hsp104 we tested the thermotolerance
activity of Hsp104 in exponentially growing
cells. We induced Hsp104 expression levels in
both strains by incubating the culture at 37 C
for 30 minute and then heat shocked at 50 C.

FIGURE 4. Expression of Hsp31 in combination with Hsp104 increases prion curing. (A) Hsp31
and p426-GPD-Hsp104 were co-transformed in the [PSIC] strain. Vector without inserts served as
controls. (B) Quantifcation of the experiments in panel A. Prion curing was increased from about
2.5% to 6% when Hsp31 was co-expressed with Hsp104 compared to the control strain (*unpaired
Student’s t-test; p 0.001, n D 3). (C) [PSIC] hsp31D strain harboring plasmids for Hsp104 and
Hsp31. (D) Quantifcation of experiments describe in panel C. The combination of Hsp104 and
Hsp31 increased prion curing in the [PSIC] hsp31D strain consistent with WT strain in A-B. (** Oneway ANOVA; p 0.001, n D 3). (E) Image of p426-GPD-Hsp42 transformed cells demonstrating
curing compared to vector only. (F) Hsp31 and p426-GPD-Hsp42 were co-transformed in the
[PSIC] strain and quantifed. The combination of Hsp42 and Hsp31 did not increase curing (ns D
not signifcant). Data and images shown are representative of at least 3 independent biological
experiments for all panels.
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The survival of cells after heat shock is dependent on Hsp104 induction, and we observed
survival in hsp31D was comparable to the isogenic WT [PSIC] strain (Fig. 5A). Moreover,
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Hsp104 was not affected by deletion of Hsp31
(Fig. 5A). In addition, we observed a slightly
elevated level of Hsp104 in the hsp31D strain
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FIGURE 5. Hsp31 interacts with Hsp104 and deletion of HSP31 does not alter Hsp104’s thermotolerance response. (A) HSP31 deletion does not impair Hsp104’s function in thermotolerance. Exponentially growing cells of the [PSIC] hsp31D and [PSIC] strains were drawn from the culture and
decimal serial dilutions were plated onto YPD plates and incubated for 2 d at 30 C in each case.
Both strains showed a comparable basal tolerance (top right image) and induced tolerance after
pretreatment at 37 C (bottom right image) for 30 min to a 50 C heat shock treatment. Left images
are non-treated cultures that serve as control. (B) Endogenous level of Hsp104 was determined in
exponentially growing cultures of [PSIC] hsp31D and [PSIC] strains in YPD media using Hsp104
specifc antibody. (C) Immunoprecipitation of Hsp31 from HSP31-9myc strain with overexpression
of Hsp104 either under GPD or GAL promoter, using anti-myc antibody followed by immunoblotting
with anti-Hsp104 antibody. Middle panel shows the successful pull down of Hsp31-9myc in all
strains using anti-myc antibody. The lower panel Hsp104 was immunoprecipitated using antiHsp104 antibody followed by immunoblotting with anti-myc antibody. Equal amount of cells lysates
were loaded in each lane.
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compared to WT, hence the expression of
Hsp104 is not compromised (Fig. 5B). Thus,
reduction in [PSIC] prion curing in the hsp31D
strain is not due to general impairment of
Hsp104 activity or expression.

Hsp104 Physically Interacts with Hsp31
The close collaboration between Hsp104 and
Hsp31 prompted us to test the physical association between them. Co-immunoprecipitation
followed by western blot analysis in yeast
lysates demonstrated that Hsp31 interacts with
Hsp104. Immunoprecipitation was performed
using HSP31-9myc genomically tagged at the
endogenous locus and overexpressing Hsp104
either under the GPD or the GAL promoter.
First, Hsp31-9myc was pulled down using antimyc antibody conjugated to agarose beads
from exponentially growing cell lysates. Western blots conﬁrmed the successful pull down of
Hsp31-9myc (Fig. 5C; middle panel). The
upper panel demonstrates the successful pulldown of Hsp104 in both GPD-HSP104 and
GAL-HSP104 expressing lysates but not in the
vector control (Fig. 5C). Similar results were
obtained with an alternative co-immunoprecipitation approach in which polyclonal antiHsp104 antibody and protein G dynabeads
were used to pull down Hsp104 followed by
western blot analysis with anti-myc antibody to
detect Hsp31. This approach conﬁrmed the
interactions and also demonstrated that Hsp31
is pulled down with strains having endogenous
levels of Hsp104 (Fig. 5C; bottom panel vector
control lane). These results demonstrate that
Hsp31 physically interacts with Hsp104 using
2 different immunoprecipitation protocols and
the Hsp31-Hsp104 interaction is detectable
under physiological expression levels.

Hsp31 Together with Hsp104 Antagonizes
Prion Dependent Toxicity of Excess
Sup35
Overexpression of full length Sup35 or its
PrD exhibits toxicity in the [PSIC] strain.48,49
The toxicity of excess Sup35 in [PSIC] or
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[PSIC] hsp31D strain was investigated. Deletion of HSP31 has no effect on Sup35 toxicity
(Fig. 6) in contrast to our previous report of
increased toxicity when a-Syn is expressed in
the hsp31D strain background.41 However, elevated levels of Hsp31 expressed from the GPD
promoter rescued [PSIC] cells from Sup35 toxicity in both WT and deleted strains. As
expected, Hsp104 reduced the toxicity of
Sup35 to a greater extent than Hsp31. Strikingly Hsp31, together with Hsp104 strongly
reduced the toxicity of Sup35 in the [PSIC]
strain (Fig. 6). We also observed the rescue
effect of sole expression of Hsp31 or Hsp104
and when expressed together in the [PSIC]
hsp31D strain. The level of rescue was not as
dramatic as in the WT strains suggesting that
the expression of endogenous Hsp31 has a role
in reducing toxicity in conjunction with heterologous expression of Hsp31 or Hsp104. The
role of endogenous Hsp31 is not clear but could
be a direct effect of chaperone activity or
because autophagy can be impaired in hsp31D
strains37 which may lead to increased proteotoxicity of Sup35.

Hsp31 and Hsp104 Modulate Sup35
Aggregation in [PSIC] Cells
Collaboration of Hsp31 with Hsp104 to
reduce Sup35 induced prion toxicity prompted
us to investigate whether this activity correlates
with protein disaggregation activity of Hsp104.
To assess the state of Sup35 in [PSIC] cells harboring Hsp31 and Hsp104 expression plasmids
(pAG415-GPD-HSP31-DsRed and p426-GPDHsp104 plasmids), we performed sedimentation analysis to determine the ratio of Sup35 in
the soluble versus aggregate forms. The individual overexpression of Hsp104 or Hsp31
resulted in a very strong signal in the insoluble
pellet fraction. However, the combination of
Hsp104 and Hsp31 markedly reduced Sup35
aggregation found in the pellet fraction and
increased the amount of Sup35 found in the soluble fraction (Fig. 7A). Soluble Sup35 was
very susceptible to proteolysis during processing of the samples as evident by the lower
molecular weight species, which is consistent
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FIGURE 6. Hsp31 and Hsp104 reduce Sup35 prion toxicity. Hsp31, Hsp104 or the indicated combination of both along with GAL-PrD-Sup35-EYFP or full length Sup35 were overexpressed in [PSIC]
and [PSIC] hsp31D strains. Decimal serial dilutions were plated onto selection plates with 2% glucose that serve as control or 2% galactose to induce the expression. Plates were incubated at
30 C for 3 d before producing the images. Hsp31 or Hsp104 rescued toxicity of GAL-PrD-Sup35EYFP or full length Sup35 in these strains. Combination of Hsp31 and Hsp104 greatly reduce the
toxicity compared to when they are individually expressed.
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with earlier reports.18,50 These results demonstrate that sole overexpression of Hsp31 does
not appear to intervene in the established prion
cycle present in a [PSIC] strain but can inhibit
aggregate formation and prionogenesis in a
[psi-] strain (Fig. 1). However, the results also
show that Hsp31 can cooperate with Hsp104 to
reduce Sup35 toxicity and simultaneously
increase Sup35 solubility.

SC-Galactose

DISCUSSION
Previous studies have demonstrated Hsp31 is
a multitasking protein involved in several cellular pathways ranging from functioning as a glutathione independent methylglyoxalase to
stress responder that acts as a molecular chaperone. In this study, we have established the
inhibitory role of Hsp31 in Sup35 prion
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associated with the vacuoles. The ﬁrst step in
de novo prion induction is the formation of a
single prion seed, also known as a
“propagon.”51,52 These seeds sequester the soluble Sup35 and grow at both ends into larger
aggregates that appeared as rings or dots under
microscopy. Moreover, it has been suggested
that not all cells with ﬂuorescent aggregates
will transform into [PSIC] prions, rather about
50% of the cells with ﬂuorescent foci will die
and some of the aggregate-containing cells

formation and its collaboration with Hsp104 to
prevent prion aggregation and toxicity in yeast.
In [PSIC] strains, soluble Sup35 protein is
depleted into insoluble prion aggregates, hence,
become less active resulting in nonsense suppression.49 The stronger [PSIC] prion phenotype is associated with larger amounts of
protein aggregates. Overexpression of Sup35
PrD-EYFP in a [psi¡] strain efﬁciently induces
de novo [PSIC] prion formation and resulting
aggregates, which appear as a peripheral ring

FIGURE 7. Hsp31 acts early in the prionogenesis process. (A) Hsp31 overexpression together with
Hsp104 decreases the aggregation of Sup35 formed by overexpression of GAL-PrD-Sup35-EYFP.
Crude lysates of cells expressing Hsp31 (pAG415-GPD-HSP31-DsRed plasmid), Hsp104 (p426GPD-Hsp104 plasmid) or both together were subjected to sedimentation analysis. Lysates were
ultracentrifuged into P (pellet) and S (soluble) fractions and analyzed by immunoblotting using
GFP-specifc antibody. (B) Model depicting the intervention of Hsp31 during the prionogenesis process but lack of involvement in an established chaperone cycle. Hsp31 and Hsp104 physically interact but it remains to be determined if this interaction is involved in a handoff of substrates.
A
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may not possess amyloids.53 Overexpression of
Hsp31 in a [psi¡] strain inhibits Sup35 aggregate formation and this was conﬁrmed by ﬂow
cytometry and SDD-AGE. These results validate the previous observation that Hsp31
reduces Sup35 aggregates in the W303 strain.41
In addition, the inhibition of Sup35 aggregation
by Hsp31 could result in the inhibition of prion
formation, because the [PINC] element
required for prion induction is present in this
strain. It should be noted that our experiments
did not assess the status of [PINC] and hence it
is possible Hsp31 expression may affect
[PINC] in addition to [PSIC]. In addition, further testing of Hsp31 with weaker [PSIC] variants could result in more robust or sustained
curing and warrant further investigation. It
should be noted that the 74D-694 strain [PSIC]
used in this study had a strong enough phenotype to resist curing by Hsp26 but was moderate at best because the strain color was pink
rather than white.
We observed that overexpression of Hsp31
results in a signiﬁcant reduction in prion induction from Sup35-PrD overexpression. However, reduced prion induction only takes place
efﬁciently when Sup35-PrD was overexpressed
for a transient period of time and upon longer
expression of Sup35-PrD, Hsp31 was unable to
reduce prion formation. Importantly, Hsp31
alone is unable to cure the [PSIC] prion indicating that it has no disaggregase activity. We postulate that the inability of curing but the
concomitant ability to prevent the formation of
de novo Sup35 SDS-resistant aggregates suggests that Hsp31 acts early in the process of
prion oligomerization but once larger oligomers are formed it is not further active in preventing prion propagation (Fig. 7B).
Hsp31 may not participate in modulating an
established prion cycle by itself but does appear
to have a role in conjunction with Hsp104
because in a strain lacking Hsp31, the level of
[PSIC] curing was reduced with Hsp104 overexpression. In addition, we showed Hsp31
overexpression promotes the elimination of
[PSIC] by Hsp104. In fact, another small heat
shock protein Hsp26 was shown to potentiate
protein disaggregation by Hsp104. Interestingly, Hsp26 is only active as a disaggregase

when it clusters together with the protein substrate and not after protein aggregation.30 A
factor in considering the mechanism of action
is that Hsp31 and the human ortholog, DJ-1,
have protein deglycase activity.54,55 Prion glycation can occur through the action of glyoxal
or methylglyoxal metabolites56 and the animal
prion protein, PrPSc, has been reported to be
modiﬁed at N terminal amino acid residues in
clinically infected hamsters.57 Further evidence
indicates that glycation can promote the stability of protein aggregates by covalent crosslinking58 suggesting the activity of a deglycase
may abrogate prion propogation. Deciphering
the contribution of the enzyme activity vs.
chaperone function of Hsp31 would delineate
the mechanisms of prion modulation by this
multi-functional enzyme. We have previously
shown that chaperone activity can be independent of the enzyme activity because overexpression of an enzymatically inactive Hsp31
mutant prevents the toxicity of a-synuclein in
yeast.41 While there is enough evidence to propose Hsp31 acts early in the process of [PSIC]
prion oligomerization process, future investigation of Hsp31 binding to the Sup35 monomer
or other early oligomer and the role of deglycation in inhibiting prion induction would assist
in elucidating the mechanism of action.
We eliminated several possible indirect
mechanisms for the cooperation of Hsp31 with
Hsp104 including the possibility that disruption
of Hsp31 might compromise Hsp104 expression and thermotolerance function (Fig. 5).
Taking into account that deletion of Hsp31
down regulates the mRNA level of Ssa3, a possible effect of Hsp31 deletion on [PSIC] prion
curing by Hsp104 could be due to imbalances
between Hsp104 and Hsp70 chaperone as these
are required for efﬁcient prion curing. However, this cannot be the case when Hsp31 is coexpressed with Hsp104, as overexpression of
Hsp31 does not alter the level of Hsp70 protein.41 An additional mechanism leading to
Hsp104-mediated curing is that modulation of
Hsp31 expression levels could have affect other
co-chaperones, which are known to have a role
in prion curing.
We also showed that Hsp31 together with
Hsp104 signiﬁcantly reduced Sup35 prion
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toxicity. These results indicate that Hsp31
cooperates with Hsp104 to potentiate Sup35
prion disaggregation and thereby prevent toxicity. Intriguingly, previous studies have shown
such cooperation between small heat shock
proteins and ATP dependent chaperones as
Hsp104 and Hsp70.31,38,59 We also observed a
signiﬁcant reduction of Sup35 toxicity by
Hsp31 overexpression alone. A number of possible explanations could account for these
results such as; Hsp31 might prevent sequestration of soluble Sup35 into already present
larger aggregates and therefore inhibit toxicity.
In addition, we have previously demonstrated
that Hsp31 can reduce oxidative stress in cells41
and this may be the reason for the rescue of
toxicity.
Intriguingly, we also found that Hsp31 physically interacts with Hsp104. Hsp104 is known
to interact with Ydj1, and co-chaperones of
Hsp90; Sti1 and Cpr7.10,26 Interestingly, Sti1
and Cpr7 are not required for Sup35 prion propagation but deletion of either of these reduced
the Sup35 prion curing by Hsp104. Hsp31 has
been documented to interact with the yeast
Hsp90, Hsp82,60 based on afﬁnity-mass spectrometry hence the interaction may involve a
bridging chaperone such as Hsp90. However,
our data is the ﬁrst demonstration of Hsp31s
interaction with Hsp104 and could mean these
chaperones may pass substrates to each other
and supports the hypothesis that Hsp31 affects
[PSIC] directly. Several studies have shown
that Hsp70 interacts with the M-domain of
Hsp104.61 In addition, co-chaperones of Hsp90
such as Sti1 and Cpr7 use a TPR motif to interact with an acidic c-terminal tail of Hsp104.62
Hsp31 does not have a TPR motif so further
investigation of the possible direct interaction
with Hsp104 could uncover a novel motif and
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mode of interaction. Although the molecular
details of the interaction are unknown, the
involvement of Hsp31 in the prion modulation
process and the apparent close functional cooperation with Hsp104 is an important step in
understanding the biological roles of this multitasking protein.

MATERIAL AND METHODS
Yeast Strains and Plasmids
[psi¡, PINC] and [PSIC] strains, derivatives
of 74D-694 [MATa, his3, leu2, trp1, ura3; suppressible marker ade1-14] were used throughout the study for prion induction, curing and
toxicity assays. The W303 HSP31-9myc strain
was used for pull down assays. Details of the
plasmid, strains and primers used in this study
are provided in the tables (Tables 1–3). Deletion of HSP31 in [PSIC] strain was obtained by
transforming a PCR product containing the
nourseothricin N- acetyl-transferase (NAT)
gene ﬂanked by HSP31 homology regions. The
primers consisted of 20 nucleotides for amplifying the NAT gene from pFA6a-NATNT2
(Euroscarf), and 50 nucleotides immediately
preceding the HSP31 start codon or after the
stop codon. The ampliﬁed product was integrated into [PSIC] and [psi¡, PINC] strain. Successful integration and deletion was conﬁrmed
by diagnostic PCR.

Yeast Growth Conditions
We used isogenic [psi¡] and [PSIC] derivatives of 74D-694 [MATa, his3, leu2, trp1, ura3;
suppressible marker ade1-14. Cells were grown
at 30 C on synthetic dextrose medium (SD;

TABLE 1. List of yeast strains used in the study.
Strain
[PSIC] 74D-694
W303-1A
[PSIC]-hsp31D
W303-HSP31-9myc
[psi¡] 74D-694

Genotype
MATa ade 1–14, his3, leu2, trp1, ura3 [PSIC PINC]
MATa can1-100 his3-11, 15 leu2-3, 112 trp1-1 ura3-1 ade2-1
W303-1A hsp31D::NATMX
W303-1A HSP31-9myc::KANMX
74D-694 MATa ade 1–14, his3, leu2, trp1, ura3 [psi¡ PINC]

Source/reference
J-C. Rochet
R. Rothstein
This study
This study
J-C. Rochet
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TABLE 2. List of plasmids used in the study.

Plasmids
pAG415GPD-HSP31dsRed
pAG415ccdB-dsRed
pAG424GAL-PrDSup35-EYFP
pLA1-Sup35
p426-GPD
p426-GPD-Hsp42
p426-GPD-Hsp104
p2HG-GPD-Hsp104
p2HG-GPD
pAG425-GAL-ccdBDsRed
pAG425-GALHsp104-DsRed

Type of
plasmid

Source/
reference

Yeast, CEN

This study

Yeast, CEN
Yeast, 2 m

Alberti et al.63
Alberti et al.8,63

Yeast, CEN
Yeast, 2 m
Yeast, 2 m
Yeast, 2 m
Yeast, 2 m
Yeast, 2 m
Yeast, 2 m

J. Shorter30
J. Shorter30
J. Shorter30
J. Shorter30
J-C.Rochet
J-C.Rochet
Addgene

Yeast, 2 m

This study

GPD-HSP31-DsRed plasmids. Cultures were
grown in SD media overnight and induced in
SC 2% rafﬁnose C 2% galactose media for
24 h. Prion aggregates were analyzed using
SDD-AGE as described previously.41 Brieﬂy,
cells were harvested by centrifugation and
spheroplasts were generated and lysed in 4 x
SDS sample buffer at room temperature for
15 min before loading onto a 1.8 % agarose gel
followed by transfer to nitrocellulose membrane. Immunoblots were performed using
anti-GFP antibody (Roche; 11814460001);
anti-DsRed antibody (Santa Cruz Biotechnology; Sc-33353) and anti-histone H3 antibody
(Abcam; ab1791).

Fluorescence Microscopy and FlowCytometry
0.7% yeast nitrogen base, 2% glucose) with
appropriate amino acid dropout mixture for
selection and maintenance of the particular
plasmid. Synthetic complete (SC) medium contains 2% rafﬁnose in place of glucose and 2%
galactose for induction of genes under the GAL
promoter. 1/ 4 YPD solid medium used in the
plating assays contains 0.5% yeast extract, 2%
peptone, and 2% glucose. Cultures were always
maintained in actively growing conditions and
OD600 was used to measure the growth rate.

SDD-AGE
[psi¡] cells were co-transformed with
pAG424-GAL-PrD-Sup35-EYFP and pAG415-

The [psi¡] strain was co-transformed with
pAG424-GAL-PrD-Sup35-EYFP and pAG415GPD-HSP31-DsRed.
Transformants
was
selected and re-streaked on SD (-tryptophan
-leucine) agar plates. Cells were grown overnight at 30 C in SD (-tryptophan -leucine)
medium and PrD-Sup35 expression was
induced for 24 h in SC (-tryptophan -leucine)
medium with 2% rafﬁnose and 2% galactose.
Cells were examined under ﬂuorescence
microscopy using a Nikon A1 confocal microscope with a Nikon Plan apochromat 60 X (NA
1.4) oil immersion objective to acquire ﬂuorescence and DIC images and were analyzed using
Image J. The identical cultures used in microscopy were also subjected to ﬂow cytometry.

TABLE 3. List of primers used in the study.
Gene/description
hsp31D

9myc tagging of HSP31

HSP31 cloning
HSP31 9myc tag diagnostic
hsp31D diagnostic

Forward

Reverse

AAGTACTTCCCACTGGCTAATTACACAG
ATAAAACTCAAACAAATTTATAATGAC
ATGGAGGCCCAGAATACCC
TCTGCGCACTCCACTGCCGTAAGATCCA
TCGACGCTTTAAAAAACCGTACGCTG
CAGGTCGAC
AAACTCGAGATGGCCCCAAAAAAAGT
TTTACTCGC
ACAGAGAATTAACGTTACTCATTCC
TTCGTGGTCGTCTCGTACTC

CTTACATCTATATAGTAGTACAAAGGAAA
TTCTAATTATCAACCTTTGGCTCACAGTA
TAGCGACCAGCATTCAC
TCCTTACATCTATATAGTAGTACAAAGGAAA
TTCTAATTATCAACCTTTGGCTCAATCGA
TGAATTCGAGCTCG
TTTGCTAGCTCAGTTTTTTAAAGCGTCGAT
GGATCTTAC
ATATTTGGATATTGGGGAAACACAT
GCAGGGCATGCTCATGTAGA
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After induction cells were collected and
washed with PBS, ﬁltered and analyzed for
EYFP ﬂuorescence intensity using the Beckman Coulter FC500 ﬂow cytometer with the
FL-1 channel. A total of 10,000 events were
acquired for each sample and data was analyzed using FlowJo software to calculate
median ﬂuorescence intensity.

Sup35 Prion Curing
Curing of [PSIC] was performed by transforming the strain with plasmids; p2HG-GPDHsp104, pAG425-GAL-Hsp104, pAG415GPD-HSP31-DsRed, p426-GPD-Hsp42 and
their corresponding vectors. For double transformation both plasmids were co-transformed
and selected on double dropout media simultaneously. Transformed cells were grown in the
SD medium at 30 C for overnight growth and
plated on 1/ 4 YPD plates which were incubated
for 3 d at 30 C and shifted for another day at
4 C for colony color development. To score for
curing, colonies with red color were counted as
[psi¡]. Cultures carrying plasmid with the GAL
promoter were grown in SC medium before
plating on 1/ 4 YPD. Plates were imaged with a
scanner and the colonies in the images were
analyzed and counted in a blind manner using
the colony counting function in Image J. Sectored colonies were counted as cured colonies.

Sup35 Prion Induction
For the induction experiment, at least 3 independent transformants with pAG424-GALPrD-Sup35-EYFP and pAG415-GPD-HSP31DsRed plasmid were grown at 30 C in SD
medium overnight, centrifuges and washed
3 times with water, and shifted to SC medium
to induce prion formation. Aliquots were withdrawn at 6, 12 and 48 h and diluted to a density
of 50,000 cells per 100 ml for plating onto 1/ 4
YPD plate. The plates were then incubated for
3 d at 30 C and another day at 4 C for color
development. Percentage of [PSIC] induction
was measured as the number of white ([PSIC]
colonies) colonies divided by the total number
of colonies.
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Prion Toxicity Assay
The [PSIC] strain was transformed with
pAL1 Sup35 and plasmids expressing Hsp31,
Hsp42 and or Hsp104 along with their corresponding vector. After selection on SD plates,
cells were grown into 5 ml of SD liquid media
with 2 % glucose at 30 C overnight. Cells were
harvested and washed 3 times with water and a
5-fold serial dilution was performed with a
starting OD600 of 0.8. Diluted samples of 5 ml
were spotted onto SD and SC plates with the
appropriate dropout selection. Plates were incubated at 30 C for 3 d and imaged with a
scanner.

Pull Down Assay
The HSP31-9myc tagged strain was transformed with plasmids pAG425-GAL-Hsp104 or
p426-GPD-Hsp104. Cells lysates were prepared
in a buffer (50 mM Tris–HCl, 1 mM EDTA,
5 mM DTT, 10% (v/v) glycerol, 0.5 M NaCl,
at pH 7.5) with freshly added protease inhibitor
cocktail (Roche). Anti-myc antibody-conjugated agarose beads were used to pull down
Hsp31 protein by incubating the beads with the
lysate at 4 C for 1 h. After the pull down, beads
were washed 3 times with PBS-T and bound
protein was eluted by boiling the sample in
SDS loading buffer before separating the proteins on SDS-PAGE and western blotting using
Hsp104 antibody (Abcam; ab69549). Immunoprecipitation was also preformed in reverse by
immobilizing Hsp104 antibody on protein G
dynabeads (Life Technology) and incubating
the total cell lysate with this complex for 1 h.
In this case, western blotting was performed
using anti-myc antibody (Sigma; M4439).

Thermotolerance Assay
WT [PSIC] and [PSIC] hsp31D strains were
grown in YPD medium starting from OD600 of
0.2 until they reach exponential growth phase
after 6 h. Equal number of cells from each
strain were incubated at 37 C to induce Hsp104
expression and then heat shocked at 50 C for
20 min. Aliquots were placed on ice before and
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after heat shock. A portion of cultures were heat
shocked at 50 C without Hsp104 induction at
37 C. Samples were collected and 5-fold dilutions were spotted on YPD medium.
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Sedimentation Assay
[PSIC] strains harboring Hsp31, Hsp104 and
appropriate co-expression vector plasmids
were grown for 12 h and centrifuged to collect
cells. Cells were washed in water and lysed at
4 C by bead beating in lysis buffer (50 mM
Tris HCl pH 7.5, 50 mM NaCl, 2 mM EDTA
and 5% Glycerol plus freshly added protease
inhibitor cocktail41). Equal volume of cold
RIPA buffer (50 mM Tris HCl pH 7.0,
150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate and 0.1 % SDS) was added to the lysate
and the mixture was vortexed for 10 s. Lysate
was centrifuged at 800 rpm for 2 min at 4 C in
a Eppendorf microcentrifuge. Lysate supernatant was subjected to ultracentrifugation at
80,000 rpm in a TLA-120.2 rotor for 30 min
using an Optima Max-XD Ultracentrifuge
(Beckman Coulter). Supernatant was collected
and pellet was re-suspended in equal volume of
lysis and RIPA buffer. Supernatant and pellet
fractions were subjected to SDS-PAGE and
immunoblotted using GFP antibody (Roche).
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